Infliximab is a chimeric anti-tumor necrosis factor-alpha monoclonal antibody. Infusion related reactions and infection are well known side effects of infliximab; however, renal complications have not been well recognized. We report on a patient with late onset-acute tubulointerstitial nephritis (ATIN) after treatment with infliximab and mesalazine for Crohn's disease. A 25-year-old woman was admitted with a purpuric rash on both lower extremities and arthralgia. She had been diagnosed with Crohn's disease 5.6 years previously and had been treated with mesalazine and infliximab. Serum creatinine level, last measured one year ago, was elevated from 0.6 mg/dL to 1.9 mg/dL. Results of urinalysis, ultrasound, and serologic examinations were normal. With a tentative diagnosis of Henoch-Schönlein purpura, oral prednisolone was given, and serum creatinine decreased to 1.46 mg/dL, but was elevated to 2.6 mg/dL again at two months after discontinuation of prednisolone. Renal biopsy indicated that ATIN was probably induced by drug, considering significant infiltration of eosinophils. Concomitant use of infliximab with mesalazine was supposed to trigger ATIN. Oral prednisolone was administered, and serum creatinine level showed partial recovery. Thus, ATIN should be suspected as a cause of renal impairment in Crohn's disease even after a long period of maintenance treatment with infliximab and mesalazine. (Korean J Gastroenterol 2014;63:308-312) 
INTRODUCTION
Acute tubulointerstitial nephritis (ATIN) is a disorder that manifests as acute kidney injury (AKI) with interstitial inflammation, edema, and tubulitis, which is usually related to drug or infection. 1 Renal dysfunction of ATIN is assumed to be reversible in most cases, and drug related ATIN should resolve with discontinuation of the responsible drug. However, one recent study showed that despite appropriate treatment, a significant proportion of ATIN cases progress to chronic kidney injury. 2 Although ATIN can be idiopathic, drug-induced ATIN is more prevalent. In an analysis of pooled data from three large studies reported in 2004, drug-induced ATIN accounted for 91 of the 128 cases (71.1%). Almost every drug is capable of inducing ATIN, and the clinical presentation and laboratory Fig. 1 . Changes of serum creatinine levels. Creatinine level showed a slight decrease after initial administration of oral prednisolone. However, it increased again when the steroid was discontinued according to infliximab treatment. Oral prednisolone (0.5 mg/kg) was reintroduced, and the serum creatinine level remained nearly stable after adalimumab treatment. ATIN). 3, 4 Here, we report on a patient who presented with delayed onset ATIN after a prolonged period of maintenance treatment with infliximab and mesalazine for Crohn's disease. 
CASE REPORT

DISCUSSION
ATIN is observed in 2-3% of all renal biopsy samples; however, the number increases to 6.5-27% when the analysis is restricted to AKI patients. 8, 9 The causes of ATIN are variable.
Idiopathic cases such as tubulointerstitial nephritis and uveitis syndrome and anti-tubular basement membrane disease have been reported. Systemic diseases such as sarcoidosis, systemic lupus erythematosus, and Sjögren's syndrome are also known to be associated with ATIN. Among various underlying causes, drug-induced ATIN is the most prevalent, consisting of more than 75% cases of ATIN, followed by infection (15%). 1, 4 Theoretically, any drug is capable of triggering ATIN.
Antibiotics, antiviral medications, anticonvulsants, analgesics, and anti-ulcer medications have frequently been associated with ATIN. 4 In the current case, the patient had been treated with infliximab and mesalazine exclusively. Several cases of delayed onset of mesalazine-induced ATIN have been reported previously. 10, 11 However, the median duration of mesalazine treatment was less than two years, and chronic interstitial nephritis with interstitial fibrosis and lymphocytic infiltration was mainly manifested in patients who experienced renal dysfunction after taking mesalazine more than 1.5 years.
ATIN in Crohn's disease with a prolonged period of maintenance treatment more than five years has rarely been reported. 11, 12 Given that the patient had been taking mesalazine for more than five years without any noticeable effects on renal function, the possibility of infliximab as a triggering agent for ATIN was suspected. Temporal association between aggravation of renal function and the interval of infliximab administration and the immunogenicity of infliximab, possibly due to its chimeric nature, 13 supported our suspicion that infliximab triggered development of ATIN in the current case. 14, 15 One case of ATIN after etanercept treatment has been reported. 16 However, the case is the first report of however, less than 10% of patients show all three findings.
Although proteinuria, hematuria, and leukocyturia may be present on urinalysis, these findings are not diagnostic for ATIN. 4 Eosinophiluria was once thought to be a typical finding;
however, its role in diagnosis of drug-induced ATIN is limited due to low sensitivity and specificity. [17] [18] [19] Renal biopsy is essential for diagnosis of ATIN and the presence of interstitial inflammation and tubulitis are the main pathologic findings. 4 In our case, purpuric rash, which may have been an extrarenal manifestation of ATIN during the first episode of renal dysfunction, was accompanied by arthralgia, which led us to misrecognize the condition as Henoch-Schönlein purpura.
The absence of abnormal findings on urinalysis initially, and the substantially long duration of exposure to infliximab, also reduced our suspicion of ATIN, preventing early diagnosis and treatment. 
